Palbociclib

  • PDF / 170,153 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 6 Downloads / 162 Views

DOWNLOAD

REPORT


1 S

Leukopenia and neutropenia: case report An approximately 48-year-old woman developed leukopenia and neutropenia during treatment with palbociclib for recurrent ovarian cancer. In 1994, the woman was diagnosed with stage III ovarian cancer at the age of 25 years. She underwent a total abdominal hysterectomy, bilateral salphingo-oophorectomy and infracolic omentectomy and received carboplatin and paclitaxel. For the subsequent 19 years, she remained disease free until 2013. In 2013, at the age of 44 years, she presented with left pleural effusion. Pleuroscopy and cytology confirmed that the pleural effusion was recurrent papillary serous carcinoma. She was treated with combination of carboplatin, paclitaxel and bevacizumab, which were stopped as she opted for a drug holiday. In 2016 (at an approximate age of 47 years), the pleural effusion worsened and she was transferred to a hospital. At that time, BRCA testing showed no BRCA1/2 mutation. Considering the long relapse-free interval, she was treated with carboplatin and pegylated liposomal doxorubicin. Clinical and radiological improvement was noted. Five months later, in April 2017 (at an approximate age of 48 years), she presented with left axillary lymphadenopathy. High-grade serous carcinoma with positive oestrogen receptor was noted. At that time, she started receiving letrozole. In May 2017, her CA125 increased and letrozole was changed to tamoxifen. However, CA125 continued to increase. She had performance status ECOG 0. Since June 2017, her therapy was chanaged to palbociclib 125mg once daily at 3-weeks on and 1-week off schedule [route not stated] along with letrozole. She tolerated palbociclib well throughout the treatment. No dose adjustments or dose delays were needed. She developed grade II leukopenia and grade II neutropenia, which were considered to be the class effects of palbociclib [time to reactions onsets and outcomes not stated]. At the last observation, the treatment was continued. Lee DW, et al. Palbociclib in the treatment of recurrent ovarian cancer. Gynecologic Oncology Reports 34: 100626, Nov 2020. Available from: URL: http://doi.org/10.1016/ 803518130 j.gore.2020.100626

0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 28 Nov 2020 No. 1832